These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20425333)

  • 21. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie.
    Raemaekers J; Burgers M; Henry-Amar M; Pinna A; Mandard A; Monfardini S; Hagenbeek A; Breed W; Carde P; Vovk M; van Hoof A; Thomas J; Noordijk E
    Ann Oncol; 1997; 8 Suppl 1():111-4. PubMed ID: 9187443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report.
    Hall GW; Katzilakis N; Pinkerton CR; Nicolin G; Ashley S; McCarthy K; Daw S; Hewitt M; Wallace WH; Shankar A
    Br J Haematol; 2007 Sep; 138(6):761-8. PubMed ID: 17760808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
    Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
    J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment of a patient with lymphocyte-predominant Hodgkin's lymphoma with yttrium-90-ibritumomab tiuxetan.
    Zojer N; Mirzaei S; Ludwig H
    Eur J Haematol; 2008 Oct; 81(4):322-4. PubMed ID: 18616515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of lymphocyte-predominant Hodgkin lymphoma.
    Engert A
    Ann Oncol; 2008 Jun; 19 Suppl 4():iv45-6. PubMed ID: 18519402
    [No Abstract]   [Full Text] [Related]  

  • 26. Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapy.
    Marcus KC; Kalish LA; Coleman CN; Shulman LN; Rosenthal DS; Canellos GP; Mauch PM
    J Clin Oncol; 1994 Dec; 12(12):2567-72. PubMed ID: 7989930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up.
    Chen RC; Chin MS; Ng AK; Feng Y; Neuberg D; Silver B; Pinkus GS; Stevenson MA; Mauch PM
    J Clin Oncol; 2010 Jan; 28(1):136-41. PubMed ID: 19933914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current treatment and immunotherapy of Hodgkin's lymphoma.
    Klimm B; Schnell R; Diehl V; Engert A
    Haematologica; 2005 Dec; 90(12):1680-92. PubMed ID: 16330443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group.
    Klimm B; Eich HT; Haverkamp H; Lohri A; Koch P; Boissevain F; Trenn G; Worst P; Dühmke E; Müller RP; Müller-Hermelink K; Pfistner B; Diehl V; Engert A;
    Ann Oncol; 2007 Feb; 18(2):357-63. PubMed ID: 17071932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl.
    Culić S; Armanda V; Kuljis D; Kuzmic I; Pranic-Kragic A; Jankovic S
    Pediatr Hematol Oncol; 2006 Dec; 23(8):661-6. PubMed ID: 17065142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin's lymphoma.
    Galán L; Sánchez AC; Cantos B; Provencio M
    Clin Transl Oncol; 2010 May; 12(5):384-6. PubMed ID: 20466624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
    Weiner MA; Leventhal BG; Marcus R; Brecher M; Ternberg J; Behm FG; Cantor A; Wharam M; Chauvenet A
    J Clin Oncol; 1991 Sep; 9(9):1591-8. PubMed ID: 1714950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab.
    Unal A; Sari I; Deniz K; Ozkan M; Kontas O; Eser B; Cetin M
    Leuk Lymphoma; 2005 Nov; 46(11):1613-7. PubMed ID: 16236615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcome of treatment for Ann Arbor Stage I Hodgkin's disease: prognostic factors for survival and freedom from progression.
    Vlachaki MT; Hagemeister FB; Fuller LM; Besa PC; Hess MA; Brown B; Cabanillas F; Cox JD
    Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):593-9. PubMed ID: 9231684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Controversies in radiotherapy for pediatric Hodgkin's lymphoma.
    Wiegner EA; Donaldson SS
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1357-66. PubMed ID: 22029056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
    Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
    J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hodgkin's disease associated with human immunodeficiency virus infection. A clinical study of 46 cases. Cooperative Study Group of Malignancies Associated with HIV Infection of Madrid.
    Rubio R
    Cancer; 1994 May; 73(9):2400-7. PubMed ID: 8168044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG).
    Diehl V; Loeffler M; Pfreundschuh M; Ruehl U; Hasenclever D; Nisters-Backes H; Sieber M; Smith K; Tesch H; Geilen W
    Ann Oncol; 1995 Nov; 6(9):901-10. PubMed ID: 8624293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of chest wall and lung invasion on outcome of stage I-II Hodgkin's lymphoma after combined modality therapy.
    Hodgson DC; Tsang RW; Pintilie M; Sun A; Wells W; Crump M; Gospodarowicz MK
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1374-81. PubMed ID: 14630276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.